Agilon Health, Inc. (NYSE:AGL) Receives Average Recommendation of "Hold" from Brokerages

Agilon Health, Inc. (NYSE:AGL - Get Free Report) has earned an average recommendation of "Hold" from the eighteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $4.79.

AGL has been the subject of a number of research analyst reports. Robert W. Baird cut their target price on Agilon Health from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Tuesday, April 15th. Wells Fargo & Company cut their price objective on Agilon Health from $6.00 to $5.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Citigroup raised Agilon Health from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $3.25 to $5.00 in a report on Friday, April 25th. Royal Bank Of Canada upped their price target on shares of Agilon Health from $3.00 to $3.50 and gave the company an "outperform" rating in a report on Wednesday, February 26th. Finally, Sanford C. Bernstein upgraded shares of Agilon Health from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $3.30 to $8.50 in a research report on Tuesday, April 8th.

Agilon Health Stock Performance

NYSE:AGL opened at $2.12 on Wednesday. The stock has a market cap of $875.50 million, a price-to-earnings ratio of -3.58 and a beta of 0.14. Agilon Health has a 1 year low of $1.50 and a 1 year high of $7.73. The business has a fifty day moving average of $3.23 and a 200-day moving average of $3.21.

Agilon Health (NYSE:AGL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.04. Agilon Health had a negative net margin of 4.04% and a negative return on equity of 45.47%. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the prior year, the firm posted ($0.02) EPS. Agilon Health's revenue was down 4.5% compared to the same quarter last year. On average, equities research analysts predict that Agilon Health will post -0.59 EPS for the current year.

Hedge Funds Weigh In On Agilon Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGL. Empowered Funds LLC acquired a new stake in Agilon Health during the 4th quarter valued at $97,000. Rhumbline Advisers grew its holdings in shares of Agilon Health by 6.2% during the fourth quarter. Rhumbline Advisers now owns 419,587 shares of the company's stock valued at $797,000 after buying an additional 24,420 shares in the last quarter. Alberta Investment Management Corp purchased a new position in shares of Agilon Health during the fourth quarter valued at $1,564,000. Ieq Capital LLC acquired a new position in Agilon Health during the fourth quarter valued at $26,000. Finally, Handelsbanken Fonder AB lifted its stake in Agilon Health by 47.9% in the 4th quarter. Handelsbanken Fonder AB now owns 75,000 shares of the company's stock worth $142,000 after acquiring an additional 24,300 shares in the last quarter.

Agilon Health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.